The ability of PDGFRB inhibitors to significantly reduce the extent of fibrosis in ARPKD organoids confirms that the PDGFRB-STAT3 pathway plays an important role in the pathogenesis of liver fibrosis. Here, STAT3 is linked to Hepatic fibrosis.